Beaumont Health is Southeast Michigan’s largest health care system (based on inpatient admissions and net patient revenue). The organization, headquartered in Southfield, Michigan, has net revenue of $4.7 billion and consists of eight hospitals with 3,375 beds, 155 outpatient sites, nearly 5,000 physicians, more than 33,000 employees and about 2,000 volunteers. In 2019, Beaumont had 179,600 discharges, 17,600 births and 577,000 emergency visits. The flagship hospital of the system is the Beaumont Hospital, Royal Oak, located in the Detroit suburb of Royal Oak, Michigan..
Occupational radiation exposure has a clear association with long-term health effects and has a particular impact on women, trainees, and supporting staff. There is a reliance on limited, traditional radiation protection and nonergonomic equipment, which carries associated orthopedic injury rates with adverse impacts on both individual career trajectories and health systems, and with significant challenges to widespread implementation of enhanced radiation protection devices. During the 2025 Society for Cardiovascular Angiography & Interventions Scientific Sessions in Washington, DC, a multidisciplinary Think Tank summit was convened and included representatives from multiple stakeholders, including other professional societies, advocacy groups, and industry partners. The focus of discussion was on the dual dangers of both ionizing radiation and the musculoskeletal injuries associated with current-generation protection equipment. This document summarizes the main points of discussion and outlines actionable next steps to advocate for more widespread implementation of enhanced radiation protection technologies and imaging systems in order to achieve ALARA+ (as low and as light as reasonably achievable).
Patients with colour vision deficiency (CVD) may not see blood in urine or stool, often the first sign of bladder or colorectal cancer, respectively. Here we sought to identify whether patients with bladder or colorectal cancer and CVD have worse outcomes when compared to matched patients without CVD, using an electronic health records research network (TriNetX). A total of 135 patients with CVD and bladder cancer showed shorter overall survival (χ2 = 4.85, P = 0.028) as compared to 135 matched patients without CVD. There was no significant difference among 187 patients with colorectal cancer and CVD, and controls. This suggests that patients with bladder cancer and CVD may be at risk of reduced survival. This is a hypothesis-generating paper that should raise clinicians’ diagnostic suspicion for bladder cancer in patients with CVD and prompt further investigation into whether screening for bladder cancer should be introduced for high-risk individuals with CVD. In a retrospective case–control study of electronic health records, patients with bladder cancer and colour vision deficiency (CVD) had a 52
Abstract Background Obesity is a well known major risk factor for cardiovascular disease, its effect on worsening hypertension, dyslipidemia, and insulin resistance leads to further increase in mortality. Despite medical advances, the toll of obesity on CV disease remains deeply concerning. This study uses national CDC WONDER data from 1999 to 2020 to explore how obesity related CV deaths have changed over time, and to find related demographic disparities. Purpose The purpose of this study is to examine national trends in obesity-associated cardiomyopathy mortality from 1999 to 2020 and to identify demographic and geographic disparities in mortality rates. The findings aim to inform targeted public health strategies to reduce obesity-related cardiovascular deaths. Method Using CDC WONDER data, we calculated AAMR per 1,000,000 for individuals aged 25 to 84 and 85+ who died from cardiomyopathy with obesity. Patient were identified by using ICD 10 codes for cardiomyopathies (I25.5, I42.0-I42.9) and obesity (E65-E68). Joinpoint regression analysis was used to estimate APC and AAPC from 1999 to 2020. Results From 1999 to 2020, the AAMR for obesity associated cardiomyopathy increased from 5.05 to 6.43 in 2004, fluctuated, then peaked at 10.76 in 2020 with AAPC 3.5 (95% CI: 3.2 to 3.8). 34,032 deaths were recorded in total. Men had higher AAMRs (9.55) than women (5.4) with AAPC in Men was 4.2 (95% CI: 3.8 to 4.8) and in women was 2.0 (95% CI: 1.6 to 2.6). Racial disparities were evident, with NH Black having the highest AAMR (12.7), followed by American Indian/Alaska Natives (12.16), NH White (7.09), Hispanic (5.02), and NH Asian/Pacific Islanders (2.41). Mortality was higher in rural areas (8.01) vs. urban areas (7.27). California had the most deaths i.e 5,592 with AAMR 10.52. Conclusion Obesity-associated myocardial disease mortality nearly doubled from 1999 to 2020, peaking in 2020. Males, NH Black individuals, and rural populations had the highest AAMRs. California recorded the most deaths. This study highlights the need for specific public health strategies to address obesity related cardiovascular risks and reduce related mortality.Image 1Image 2
Uterine rupture is a rare and potentially fatal complication seen after vaginal birth after cesarean section (VBAC). We present two cases of uterine dehiscence and uterine rupture following successful VBAC, each demonstrating distinct clinical presentations and outcomes. A 34-year-old gravida 2, para 1001 developed persistent brisk bleeding after a successful VBAC, raising concern for uterine dehiscence. She was found to have a 2-cm anterior uterine defect that was successfully repaired. In contrast, a 31-year-old gravida 2, para 1001 developed hemodynamic instability following a successful VBAC and was found to have a 6-cm uterine rupture of the anterior wall, contiguous with a 4-cm posterior defect. The patient was started on a massive transfusion protocol and initially stabilized in the operating room; however, due to recurrent hemodynamic instability, an abdominal hysterectomy was performed. These cases highlight a rare yet serious complication of trial of labor after cesarean, with uterine dehiscence and rupture occurring at the prior hysterotomy site following successful VBAC. There is limited literature on the postpartum diagnosis of uterine rupture and dehiscence in the setting of VBAC; this report provides insight into their variable clinical presentations and management.
Background The purpose of this study was to provide 2-year postoperative clinical outcomes and survivorship of a novel, fully 3D printed humeral prosthesis. Methods This is a prospective case series of 34 patients who underwent anatomic total shoulder arthroplasty (TSA) with a fully 3D printed humeral prosthesis. Minimum postoperative follow-up was two years. Patient demographics, clinical outcomes, and radiographic outcomes were collected. X-rays were examined for radiolucent lines surrounding the implant. The primary outcome was TSA survivorship. Secondary outcomes were patient-reported outcome metric (PROM) scores and radiographic findings. Results At a minimum follow-up of 2 years, there were no revisions or reoperations with a prosthetic survivorship of 100%. At final follow-up, patients had significant improvement in American Shoulder and Elbow Surgeons (ASES) and Visual Analogue Scale (VAS) scores (p<0.001), with a mean postoperative ASES of 93 and VAS of 0.5. The rate of any peri-prosthetic radiolucent line on XR was 2 of 34 (6%). All identified radiolucent lines were <0.5 mm. Discussion The results of early clinical follow-up of this fully 3D printed off-the-shelf humeral prosthetic are encouraging. Postoperative radiolucent lines appear to be minimal in thickness, infrequent, and of unclear clinical significance given 100% survivorship and reassuring PROMs. Further clinical follow-up of this and other 3D printed systems is necessary to confirm that additive manufacturing is a mechanically durable and viable method for off-the-shelf TSA manufacturing.
